Neem leaf glucosamine stimulates Interleukin-2 (IL-2) in swiss albino mice by Santhosh Kumar Venugopalan et al.
 1 
 
 
Neem leaf glucosamine stimulates Interleukin-2 (IL-2) in swiss albino mice  
 
Venugopalan Santhosh Kumar, 1,2*  V. Navaratnam, 1,3   A. Rajasekaran, 2   N.K.Nair 1  
 
1Centre for Drug Research, Universiti Sains Malaysia, 11800 Penang, Malaysia 
2KMCH College of Pharmacy, Coimbatore 641048, Tamilnadu, India 
3Drugs for Neglected Diseases Initiative (DNDi), 1 Place St Gervais, CH-1201  
  Geneva, Switzerland 
 
Abstracts 
 
   Neem leaf glucosamine mediated immune stimulation was studied in male swiss 
albino mice. Mice were treated with three doses of Neem leaf glucosamine  
(266, 400 and 800 µg/30gm mouse, intraperitoneal injection) one dose per week for 
four weeks. At doses of 266, 400 and 800 µg/30gm mouse a significant increase in the 
Interleukin-2 in mice serum was observed when compared to the control group and 
also increase in relative organ weight of thymus was observed but there was mild 
increase on liver and kidney weights. Immune Stimulatory response of the Neem leaf 
glucosamine was also observed in the T-lymphocytes proliferation. Overall, Neem 
leaf glucosamine showed a stimulatory effect on immune functions in mice. The 
immunostimulatory effect of Neem leaf glucosamine as reported in this study will 
have special relevance for the prophylactic and therapeutic potential treatment of 
various infectious diseases and antitumor activity. 
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1.  Introduction 
 
   Neem tree (Azadirachta indica A. Juss.) is a sacred gift of nature, mainly cultivated 
in Indian subcontinent [1]. Neem is an omnipotent tree. Neem is a member of the 
mahogany family, Meliaceae. Every part of this tree has been used as traditional 
Indian medicine for household remedy, against various human diseases [2]. In 1992,  
US National Academy of Science published a report entitled, ‘Neem-a tree for solving 
global problem’ [3]. The first recorded use of Neem is attributed to the ancient East 
Indian ‘Harrappa Culture’ which added the plant to dozens of health and beauty aids 
4500 years ago. 
 
   Azadirachta indica A. juss (neem) is well known in India and its neighbouring 
countries for more than 2000 years as one of the most versatile medicinal plants. The 
rural Indian population chiefly use water-soluble components of neem leaf in their daily 
life for prevention and treatment of various ailments [4]. There are reports showing the 
effectiveness of these components in various diseases [5,6]. 
 
   Neem leaf contains several valuable components such as terpenoids, azadirone and 
its derivatives are important [7].  
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   Numerous scientific reports validate the traditional uses of Neem in both the 
maintenance of general health and skin care. Practically every part of 
Azadirachta indica (leaves, bark, fruit, flowers, oil, and gum) have been reported to 
be associated with various remedial properties [8,9] such as antimicrobial effects[10], 
storage behaviour [11], reduction of paracetamol-induced liver damage [12], enhancer 
of hepatic glutathione and glutathione-dependent enzymes [13], in vitro antiviral 
activity [14], insecticidal activity [15], antibacterial agent [16].    
 
   Noting the strong manifestation of the immunomodulating activity reported in the 
literature of neem, it is proposed to embark upon a detailed characterization of the active 
compound present in aqueous extract of Neem leaf and immunopharmacological study  
of this phenomenon with a view of establishing its efficacy as a safe immune booster. 
This study will have special relevance for the prophylactic and therapeutic potential 
treatment of various infectious diseases. 
 
   In the present study, we have isolated the Neem leaf glucosamine from the aqueous 
extract of Neem leaf and investigated the characterization of Neem leaf glucosamine 
and immunomodulatory activity of Neem leaf glucosamine in swiss wistar albino 
mice.  
 
 
2.  Materials and Methods 
 
2.1.  Preparation of Neem leaf extracts by cold extraction 
 
    Neem (Azadirachta indica) is found widely in the Sungai Petani region, 
Malaysia.The plant leaves were separated from other parts washed and shade dried. 
Dried leaves were chopped into small pieces and made into coarse powder and passed 
through a 10-mesh sieve. Neem leaf extracts were prepared using 660 g of the air 
dried and powdered neem leaf material with various solvents of different polarity 
(hexane, chloroform, methanol, and water).   
 
 
2.2.  Isolation and structure elucidation of Neem leaf glucosamine  
 
   Aqueous neem leaf extract (21.23 g) was subjected to column chromatography. 
of the fractionated aqueous neem leaf extract (4.25 g) were subjected to HPLC to 
separate the compounds. Aqueous neem leaf extract was dissolved in 
acetonitrile/water (60:40) and the soluble compounds was concentrated and subjected 
to TLC and HPLC [17, 18]. The TLC mobile phase system was acetonitrile/water 
(6:4). TLC results showed only one spot before and after being treated with sulphuric 
acid and it was observed under visible light at 254nm. The Rf value observed was 
0.75. The sample 0.1mg/1ml, injection volume 20µl was added to a Phenomenex – 
5u(Luna) C18 column, 4.6 X 250mm with the flow rate of 0.5ml/min and the mode 
was isocratic. The detection wavelength was 215nm. Single high intensity peak was 
observed in the HPLC and it was collected. The yield of the isolated neem leaf 
compound was 150 mg.  
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   Neem leaf glucosamine was isolated from the aqueous neem leaf extract by HPLC 
and structure elucidation was performed by NMR. 
 
   The isolated neem leaf compound were subjected to NMR for structure elucidation 
[19 & 20] .  
   
  
Chromatogram of Fractionated aqueous neem leaf extract obtained by HPLC 
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NMR interpretation for Isolated Water Neem Leaves Compound 
 
S.No Signals in 13C NMR Signals in 1H NMR Assignment 
1 178.665 - Carbonyl carbon 
2 98.01, 85.209 7.2 – 6.8 C-O-C carbons 
3 71.54, 73.59 3.1 – 3.8 CH-OH carbons 
4 64.007  2.1 CH2-OH carbon 
5 42.07 2.2  to  2.9 CH-NH carbon 
6 26.76 1.28 Methyl group 
7 - 4.2  to  4.5 All hydroxyl 
protons 
8 Mass values:  (m/z)  
Molecular ion peak: 221(m-1) 
Fragments: 200.0, 162.3, 146.1, 104.0, 80.0 ( other peaks may be due to 
the coupling of various other fragments) 
 
Probable structure 
 
                                       
 
                                              GLUCOSAMINE 
 
Molecular Weight   –  221.21 
Molecular Formula –  C8H15O6N 
 
IUPAC Name 
 
N-(3R,4R,5S,6R)-tetrahydro-2,4,5-trihydroxy-6-(hydroxymethyl)-2H-pyran-3-yl) 
acetamide 
 
 
     #   Atom   Molar Mass (MM) 
         (g/mol) 
Subtotal Mass 
        (%) 
Subtotal Mass 
     (g/mol) 
8 C 12.01 43.44 96.09 
15 H 1.01 6.83 15.12 
6 O 16.00 43.40 96.00 
1 N 14.01 6.33 14.01 
Total Molecular Weight: 221.21 
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2.3.  Animals 
 
   Male Swiss Wistar mice weighing 25-30g were used. Dry pellet diet and water were 
given ad libitum. Animals were maintained and treated according to the guidelines 
established by the Institutional Animal Care and Ethics Committee.  
 
 
2.4.  Acute Toxicity Studies 
 
   Acute toxicity was performed as per organization for economic co-operation for 
development (OECD) guideline 423 method [21]. Three groups of animals were selected 
(6 mice/group). Male Swiss Wistar mice were injected single dose of Neem leaf 
glucosamine by intraperitoneal route [22]. Animals are fasted 3 h prior to dosing (food 
was withheld for 3 h but not water). Following the period of fasting animals was weighed 
and test substance was administered orally at a dose of 1mg, 2mg, 4mg/30gm mouse. 
After the Neem leaf glucosamine administration, food was withheld 2 h in mice. Animals 
are observed individually after at least once during the first 30 minutes, periodically 
during the first 24 hrs, with special attention given during the first 4 hrs, and daily 
thereafter, for a total of 14 days.  
 
2.5  Immunizations 
 
   Four groups of male swiss wistar mice were selected for the experiment. Group one 
served as a control (0.9% Phosphate Buffer Saline). Three groups of male swiss wistar 
mice were (10 mice/group) intraperitoneally injected with Neem leaf glucosamine at the 
dose of 266 µg/30 gm mouse, 400 µg/30 gm mouse & 800 µg/30 gm mouse weekly for 4 
weeks [23]. The animal body weights were obtained weekly to determine the effects of 
Neem leaf glucosamine on body weight. At the end of the experimental period the blood 
samples of the mice were collected by terminal procedure cardiac puncture and the mice 
was sacrificed by cervical dislocation. The serum obtained from the centrifugation 
process was subjected for the measurement of the Interleukin-2 (IL-2) concentration by 
Enzyme linked immunosorbent assay (ELISA). Thymus, livers and kidneys were excised 
from the mice and weighed and was preserved in formalin for histopathological studies. 
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2.6  Enzyme linked immunosorbent assay (ELISA) 
 
   The RayBio® Mouse IL-2 ELISA (Enzyme-Linked Immunosorbent Assay) kit was 
used. It is an in vitro enzyme-linked immunosorbent assay for the quantitative 
measurement of mouse IL-2 in serum, plasma and cell culture supernatants [24]. This 
assay employs an antibody specific for mouse IL-2 coated on a 96-well plate. Standards 
and samples are pipetted into the wells and IL-2 present in a sample is bound to the wells 
by the immobilized antibody. The wells are washed and biotinylated anti-mouse IL-2 
antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated 
streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate 
solution is added to the wells and color develops in proportion to the amount of IL-2 
bound. The Stop Solution changes the color from blue to yellow, and the intensity of the 
color is measured at 450 nm. 
 
2.7  Histopathological studies  
 
    Histopathological Studies of the thymus, liver and kidneys of the Neem leaf 
glucosamine treated mice groups (266µgm/30gm mouse, 400µgm/30gm mouse & 
800µgm/30gm mouse) was carriedout. 
 
2.8  Statistical Analysis 
 
   All data represents the mean ± standard deviation (SD). Significance of differences 
between the data obtained from different groups of mice was analyzed by two sample 
independent ‘t’ test, one way analysis of Variance (one way - ANOVA) [25], Post Hoc 
Test, Simple bar diagram and Multiple bar diagram. p˂ 0.05 was considered to indicate 
statistical significance. 
 
 
3.  Results 
 
3.1  Neem leaf glucosamine did not induce drug related toxicity 
 
   Single dose of Neem leaf glucosamine was injected to three groups of male swiss 
wistar mice at a dose of 1mg, 2mg, 4mg/30gm mouse. Showed normal activity in 
alertness, touch response, light reflex, pain response, righting reflex, gripping strength, 
pinna and corneal reflex, pupil size, urination, salivation, skin colour, lacrimation. 
Tremors, convulsion, grooming and writhing are absent.  
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3.2 Neem leaf glucosamine is effective as an immune stimulant to enhance the 
interleukin-2 (IL-2) concentration in mice serum  
 
   Three groups of Male Swiss Wistar mice were immunized with Neem leaf glucosamine 
at the dose of 266 µg/30 gm mouse, 400 µg/30 gm mouse and 800 µg/30 gm mouse 
weekly for 4 weeks.  
 
  (Fig. 1;  Table 1 and 2) show the IL-2 concentration in mice serum were significantly 
increased from the three different dose of the Neem leaf glucosamine (266 µgm/30gm 
mouse, 400 µgm/30gm mouse & 800 µgm/30gm mouse) treated group when compared to 
the control group. The increase in the dose of the Neem leaf glucosamine treated group 
significantly showed an increase in the Interleukin-2 (IL-2) concentration in mice serum 
when compared to the control group. 
 
 
 
 
 
Fig. 1;  Table 1 and 2: 
Neem leaf glucosamine auguments Interleukin-2 (IL-2) in mice serum. 
Four groups of mice (n=10 in each group). Three groups of mice were immunized weekly 
for 4 weeks with Neem leaf glucosamine at the dose of 266 µg/30 gm mouse, 400 µg/30 
gm mouse and 800 µg/30 gm mouse. Serum was tested for the concentration of IL-2 by 
ELISA. p˂ 0.05, when Neem leaf glucosamine (266 µg/30 gm mouse, 400 µg/30 gm 
mouse and 800 µg/30 gm mouse) was compared with control.  
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Table 1: T-test 
 
 
Group Statistics 
 
  Groups Mean 
Std. 
Deviation T Sig 
IL-2 concentration 
in mice serum pg / 
ml 
Control IL-2 
20.5000 1.71594   
  Neem leaf 
glucosamine 
266µg/30gm 
97.2000 13.07075 18.399 0.000 
 Neem leaf 
glucosamine 
400µg/30gm 
204.4000 49.69060 11.696 0.000 
 Neem leaf 
glucosamine  
800µg/30gm 
233.2000 20.57399 32.579 0.000 
 
 
 
Table 2: Oneway Analysis of Variance (One way ANOVA)  
 
Descriptives 
 
   Mean 
Std. 
Deviation 
Control IL-2 20.5000 1.71594 
Neem leaf 
glucosamine 
266µg/30gm 
97.2000 13.07075 
Neem leaf 
glucosamine 
400µg/30gm 
204.4000 49.69060 
 Neem leaf 
glucosamine 
800µg/30gm 
233.2000 20.57399 
Total 138.8250 90.15624 
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ANOVA 
 
 
  
Sum of 
Squares df 
Mean 
Square F Sig. 
Between 
Groups 289401.675 3 96467.225 125.845 .000 
Within Groups 27596.100 36 766.558     
Total 316997.775 39       
 
 
Post Hoc Tests             Multiple Comparisons    Tukey HSD     
   *  The mean difference is significant at the .05 level. 
(I) Groups (J) Groups 
Mean 
Difference 
(I-J) Std. Error Sig. 
          
Control IL-2 Neem leaf glucosamine 
266µg/30gm -76.7000(*) 12.38191 .000 
  Neem leaf glucosamine 
400µg/30gm 
-
183.9000(*) 12.38191 .000 
   Neem leaf glucosamine 
800µg/30gm 
-
212.7000(*) 12.38191 .000 
Neem leaf 
glucosamine 
266µg/30gm 
Control IL-2 
76.7000(*) 12.38191 .000 
  Neem leaf glucosamine 
400µg/30gm 
-
107.2000(*) 12.38191 .000 
   Neem leaf  
glucosamine 
800µg/30gm 
-
136.0000(*) 12.38191 .000 
Neem leaf 
glucosamine 
400µg/30gm 
Control IL-2 
183.9000(*) 12.38191 .000 
  Neem leaf glucosamine 
266µg/30gm 107.2000(*) 12.38191 .000 
  Neem leaf glucosamine 
800µg/30gm -28.8000 12.38191 .111 
Neem leaf 
glucosamine  
800µg/30gm 
Control IL-2 
212.7000(*) 12.38191 .000 
  Neem leaf glucosamine 
266µg/30gm 136.0000(*) 12.38191 .000 
  Neem leaf glucosamine 
400µg/30gm 28.8000 12.38191 .111 
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3.3  Neem leaf glucosamine increases the body weight of mice 
 
  There was a significant increase in the 2nd, 3rd & 4th week of mice body weight of all the 
three doses of Neem leaf glucosamine treated groups when compared to the control group 
(Fig. 2; Table 3 and 4). Anova analysis of mice body weight in 2nd, 3rd & 4th week 
showed significant in all the Neem leaf glucosamine treated groups (200µgm/30 gm 
mouse, 400µgm/30 gm mouse & 800µgm/30 gm mouse) when compared to the control 
group. 800µgm/30 gm mouse of the Neem leaves compound (glucosamine) treated group 
showed high mean value when compared to all other groups.   
 
    
    
   Fig. 2; Table 3 and 4: Neem leaf glucosamine increases the body weight of mice.  
Significant increase in mice body weight in 2nd, 3rd & 4th week was observed in the Neem 
leaf glucosamine treated groups (200µgm/30 gm mouse, 400µgm/30 gm mouse & 
800µgm/30 gm mouse) when compared to the control group. 
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Table 3: T-test  
Group Statistics 
 
  Groups Mean 
Std. 
Deviation t Sig. 
Mice weight 
(gms) 
Control 1st week 26.7680 .41041   
  266µg/30gm 1st 
week 26.9790 .28411 1.337 0.198 
 400µg/30gm 1st 
week 26.8250 .47671 0.287 0.778 
 800µg/30gm 1st 
week 26.9390 .56021 0.779 0.446 
 
  
Group Statistics 
 
  Groups Mean 
Std. 
Deviation T Sig. 
Mice weight 
(gms) 
Control 2nd week 27.2590 .50865 9.121 0.000 
  266µg/30gm 2nd 
week 29.9620 .78709   
 400µg/30gm 2nd 
week 30.2740 .89018 9.299 0.000 
 800µg/30gm 2nd 
week 30.4370 1.28651 7.264 0.000 
 
 
Group Statistics 
 
  Groups Mean 
Std. 
Deviation T Sig. 
Mice weight 
(gms) 
Control 3rd week 27.5490 .42094   
  266µg/30gm 3rd 
week 31.0310 .99129 10.224 0.000 
 400µg/30gm 3rd 
week 31.7060 1.03662 11.749 0.000 
 800µg/30gm 3rd 
week 31.9860 1.06621 12.240 0.000 
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Group Statistics 
 
  Groups Mean 
Std. 
Deviation T Sig. 
Mice weight 
(gms) 
Control 4th week 27.8780 .78690   
  266µg/30gm 4th 
week 32.1750 .45125 14.980 0.000 
 400µg/30gm 4th 
week 33.1010 .51731 17.539 0.000 
 800µg/30gm 4th 
week 33.6840 .41578 20.630 0.000 
 
 
 
 
Table 4: ANOVA 
 
Descriptives 
  
Mice weight (gms)  
  Mean 
Std. 
Deviation 
Control 1st 
week 26.7680 .41041 
Control 2nd 
week 27.2590 .50865 
Control 3rd 
week 27.5490 .42094 
Control 4th 
week 27.8780 .78690 
Total 27.3635 .67289 
 
 
ANOVA 
 
Mice weight (gms)  
  
Sum of 
Squares df 
Mean 
Square F Sig. 
Between 
Groups 6.647 3 2.216 7.243 .001 
Within Groups 11.012 36 .306     
Total 17.659 39       
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Descriptives 
 
Mice weight (gms)  
  Mean 
Std. 
Deviation 
266µg/30gm 1st 
week 26.9790 .28411 
266µg/30gm 2nd 
week 29.9620 .78709 
266µg/30gm 3rd 
week 31.0310 .99129 
266µg/30gm 4th 
week 32.1750 .45125 
Total 30.0368 2.06397 
 
ANOVA 
 
Mice weight (gms)  
  
Sum of 
Squares df 
Mean 
Square F Sig. 
Between 
Groups 149.161 3 49.720 105.423 .000 
Within Groups 16.979 36 .472     
Total 166.139 39       
 
 
Descriptives 
 
Mice weight (gms)  
  Mean 
Std. 
Deviation 
400µg/30gm 1st 
week 26.8250 .47671 
400µg/30gm 2nd 
week 30.2740 .89018 
400µg/30gm 3rd 
week 31.7060 1.03662 
400µg/30gm 4th 
week 33.1010 .51731 
Total 30.4765 2.47551 
 
ANOVA 
Mice weight (gms)  
  
Sum of 
Squares df 
Mean 
Square F Sig. 
Between 
Groups 217.741 3 72.580 122.920 .000 
Within Groups 21.257 36 .590     
Total 238.998 39       
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Descriptives 
 
Mice weight (gms)  
  Mean 
Std. 
Deviation 
800µg/30gm 1st 
week 26.9390 .56021 
800µg/30gm 2nd 
week 30.4370 1.28651 
800µg/30gm 3rd 
week 31.9860 1.06621 
800µg/30gm 4th 
week 33.6840 .41578 
Total 30.7615 2.66545 
 
 
ANOVA 
 
Mice weight (gms)  
  
Sum of 
Squares df 
Mean 
Square F Sig. 
Between 
Groups 247.572 3 82.524 100.681 .000 
Within Groups 29.508 36 .820     
Total 277.080 39       
 
 
 
 
 
3.4  Neem leaf glucosamine increases the organ weight of mice 
 
   Significant increase in the mice organ weight (thymus, liver & kidney) was observed in 
the Neem leaf glucosamine treated groups (200µgm/30 gm mouse, 400µgm/30 gm mouse 
& 800µgm/30 gm mouse) when compared to the control group. 800µgm/30 gm mouse of 
the Neem leaf glucosamine treated group showed very high mean value when compared 
to all other groups (Table 5,6,7).   
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Table 5: T-test 
Group Statistics 
 
  Groups N Mean 
Std. 
Deviation T Sig. 
Thymus Weight 
(gms) 
Control 10 .04130 .002541   
  266 µgm/30gm 10 .05790 .001663 17.286 0.000 
 400 µgm/30 gm 10 .06840 .001506 29.017 0.000 
 800 µgm/30 gm 10 .07930 .001160 43.027 0.000 
 
 
Oneway 
Descriptives 
 
Thymus Weight (gms)  
  Mean 
Std. 
Deviation 
Control .04130 .002541 
266 
µgm/30gm .05790 .001663 
400 µgm/30 
gm .06840 .001506 
800 µgm/30 
gm .07930 .001160 
Total .06173 .014294 
 
 
ANOVA 
 
Thymus Weight (gms)  
  
Sum of 
Squares df 
Mean 
Square F Sig. 
Between 
Groups .008 3 .003 815.842 .000 
Within Groups .000 36 .000     
Total .008 39       
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Post Hoc Tests 
Multiple Comparisons 
 
Dependent Variable: Thymus Weight (gms)  
Tukey HSD  
 
(I) Groups (J) Groups 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
          
Control 266 
µgm/30gm -.01660(*) .000801 .000 
  400 µgm/30 
gm -.02710(*) .000801 .000 
  800 µgm/30 
gm -.03800(*) .000801 .000 
266 
µgm/30gm 
Control .01660(*) .000801 .000 
  400 µgm/30 
gm -.01050(*) .000801 .000 
  800 µgm/30 
gm -.02140(*) .000801 .000 
400 µgm/30 
gm 
Control .02710(*) .000801 .000 
  266 
µgm/30gm .01050(*) .000801 .000 
  800 µgm/30 
gm -.01090(*) .000801 .000 
800 µgm/30 
gm 
Control .03800(*) .000801 .000 
  266 
µgm/30gm .02140(*) .000801 .000 
  400 µgm/30 
gm .01090(*) .000801 .000 
*  The mean difference is significant at the .05 level. 
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Table 6: T-test 
Liver Weight (gm) 
 
  
Group Statistics 
 
  Groups N Mean 
Std. 
Deviation T Sig. 
Liver Weight 
(gms) 
Control 10 1.34580 .108693   
  266 µgm/30gm 10 1.46240 .016595 3.353 0.008 
 400 µgm/30 
gm 10 1.49040 .010916 4.186 0.002 
 800 µgm/30 
gm 10 1.52730 .020489 5.189 0.000 
 
 
Oneway 
 
Descriptives 
 
Liver Weight (gms)  
  Mean 
Std. 
Deviation 
Control 1.34580 .108693 
266 
µgm/30gm 1.46240 .016595 
400 µgm/30 
gm 1.49040 .010916 
800 µgm/30 
gm 1.52730 .020489 
Total 1.45647 .087438 
 
 
ANOVA 
 
Liver Weight (gms)  
  
Sum of 
Squares df 
Mean 
Square F Sig. 
Between 
Groups .185 3 .062 19.481 .000 
Within Groups .114 36 .003     
Total .298 39       
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Post Hoc Tests 
 
Multiple Comparisons 
 
Dependent Variable: Liver Weight (gm)  
Tukey HSD  
(I) Groups (J) Groups 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
          
Control 266 
µgm/30gm -.11660(*) .025128 .000 
  400 µgm/30 
gm -.14460(*) .025128 .000 
  800 µgm/30 
gm -.18150(*) .025128 .000 
266 
µgm/30gm 
Control .11660(*) .025128 .000 
  400 µgm/30 
gm -.02800 .025128 .683 
  800 µgm/30 
gm -.06490 .025128 .064 
400 µgm/30 
gm 
Control .14460(*) .025128 .000 
  266 
µgm/30gm .02800 .025128 .683 
  800 µgm/30 
gm -.03690 .025128 .467 
800 µgm/30 
gm 
Control .18150(*) .025128 .000 
  266 
µgm/30gm .06490 .025128 .064 
  400 µgm/30 
gm .03690 .025128 .467 
*  The mean difference is significant at the .05 level. 
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Table 7: T-test 
Kidney weight (gm) 
 
Group Statistics 
 
  Groups N Mean 
Std. 
Deviation T Sig. 
Kidney Weight 
(gms) 
Control 10 .32470 .020532   
  266 µgm/30gm 10 .37450 .007735 7.178 0.000 
 400 µgm/30 gm 10 .39620 .012943 9.316 0.000 
 800 µgm/30 gm 10 .41470 .011255 12.155 0.000 
 
 
Oneway 
 
Descriptives 
 
Kidney Weight (gms)  
  Mean 
Std. 
Deviation 
Control .32470 .020532 
266 
µgm/30gm .37450 .007735 
400 µgm/30 
gm .39620 .012943 
800 µgm/30 
gm .41470 .011255 
Total .37753 .036614 
 
ANOVA 
 
Kidney Weight (gms)  
  
Sum of 
Squares df 
Mean 
Square F Sig. 
Between 
Groups .045 3 .015 77.883 .000 
Within Groups .007 36 .000     
Total .052 39       
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Post Hoc Tests 
 
Multiple Comparisons 
 
Tukey Method 
(I) Groups (J) Groups 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
          
Control 266 
µgm/30gm -.04980(*) .006227 .000 
  400 µgm/30 
gm -.07150(*) .006227 .000 
  800 µgm/30 
gm -.09000(*) .006227 .000 
266 
µgm/30gm 
Control .04980(*) .006227 .000 
  400 µgm/30 
gm -.02170(*) .006227 .007 
  800 µgm/30 
gm -.04020(*) .006227 .000 
400 µgm/30 
gm 
Control .07150(*) .006227 .000 
  266 
µgm/30gm .02170(*) .006227 .007 
  800 µgm/30 
gm -.01850(*) .006227 .026 
800 µgm/30 
gm 
Control .09000(*) .006227 .000 
  266 
µgm/30gm .04020(*) .006227 .000 
  400 µgm/30 
gm .01850(*) .006227 .026 
*  The mean difference is significant at the .05 level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.5
92
3.
1 
: P
os
te
d 
24
 A
pr
 2
01
1
 22 
3.5. Neem leaf glucosamine causes T-lymphocytes proliferation 
 
  Histopathological Studies of the Thymus of the Neem leaf glucosamine treated groups 
(266µgm/30gm mouse, 400µgm/30gm mouse & 800µgm/30gm mouse) showed the 
proliferation of T-lymphocytes (Fig. 3. B,C,D) when compared to the control group  
(Fig. 3. A). This shows that the three different doses of the Neem leaf glucosamine 
treated group possess immunostimulating activity. 
 
  Histopathological Studies of the Liver and Kidneys of the control group and the Neem 
leaf glucosamine treated groups (266µgm/30gm mouse, 400µgm/30gm mouse & 
800µgm/30gm mouse) did not show any pathological changes. This finding indicates that 
Neem leaf glucosamine does not cause any hepatic and renal damage in the above 
mentioned three dose levels.  
 
 
 
 
 
                        A                                                                B    
 
Mice Thymus
 
 
                         C                                                              D 
 
Fig. 3. A – Control 
B,C,D - Neem leaf glucosamine at the dose of 200µgm/30 gm mouse,  
400µgm/30 gm mouse & 800µgm/30 gm mouse showerd proliferation of T-lymphocytes.   
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4.  Discussion and Conclusion 
 
   We identified and characterized the active component of Aqueous Neem leaf extract  
that is responsible for immunostimulatory activity. Neem leaf glucosamine was found to 
be the active component that is responsible for immunostimulatory activity in swiss 
albino mice.  
 
  We investigated the acute toxicity of Neem leaf glucosamine in male swiss albino mice. 
From the acute toxicity studies it was observed that the administration of single dose of 
Neem leaf glucosamine did not induce drug related toxicity and mortality in the mice up 
to 4mg/30 g mouse intraperitoneally. 
 
  Next, we investigated, the potential of Neem leaf glucosamine as an immune stimulant 
by enhancing interleukin-2 (IL-2) concentration in mice serum and proliferation of  
T-lymphocytes. Neem leaf was selected due to proved non-toxicity of neem preparations 
during regular human consumption. Our ELISA results clearly suggest that Neem leaf 
glucosamine stimulate the immune system.  
 
  Significant increase in the concentration of IL-2 was observed in the 266 µg/30 gm 
mouse, 400 µg/30 gm mouse and 800 µg/30 gm mouse Neem leaf glucosamine treated 
groups when compared to the control group. The highest concentration of IL-2 was 
observed at the dose of 800 µg/30 gm mouse Neem leaf glucosamine treated groups.  
 
  Significant increase in mice body weight in 2nd, 3rd & 4th week was observed in the 
Neem leaf glucosamine treated groups (200µgm/30 gm mouse, 400µgm/30 gm mouse & 
800µgm/30 gm mouse) when compared to the control group. Significant increase in the 
mice organ weight (thymus, liver & kidney) was also observed in the Neem leaf 
glucosamine treated groups (200µgm/30 gm mouse, 400µgm/30 gm mouse & 
800µgm/30 gm mouse) when compared to the control group. No toxic effect on organs of 
this dose was also observed by histopathological investigations.  
 
  Histopathological Studies of the Thymus of the Neem leaf glucosamine treated groups 
(266µgm/30gm mouse, 400µgm/30gm mouse & 800µgm/30gm mouse) showed the 
proliferation of T-lymphocytes when compared to the control group. This show the three 
different doses of the Neem leaf glucosamine treated group possess immunostimulating 
activity. 
 
  IL-2 is a protein of 133 amino acids (15.4 kDa). It is produced mainly by T-cells 
expressing the surface antigen CD4 following cell activation by mitogens or allogens 
under physiological conditions. Genetically engineered IL-2 has frequent and important 
adverse effects. Toxic effects observed are systemic (fever, chills, malaise), 
hemodynamic (capillary leak syndrome, hypotension), cardiac (arrhythmia, infarction), 
renal (renal dysfunction), infectious (septicemia), cutaneous, hematologic, 
gastrointestinal, endocrinologic and metabolic [26].  
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   To overcome the genetically engineered IL-2 adverse effectes, we found that natural 
products such as Neem leaf glucosamine’s  increased IL-2 effect as reported in this 
study will have special relevance for the prophylactic and therapeutic potential 
treatment of various infectious diseases and anti-tumor activity for a variety of tumor 
cell types since it can supports the proliferation and clonal expansion of T-cells that 
specifically attack certain tumor types with very less adverse effects. 
  
  Thus, results of the present study clearly suggest that Neem leaf glucosamine isolated 
from the aqueous Neem leaf extract can serve as a potential immunostiumlant. The effect 
of Neem leaf glucosamine in treating cancer and infectious diseases such as dengue, HIV, 
H5N1 bird flu, viral hepatitis needs to be explored.  
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